Bioluminescent imaging assessment was performed at 4 weeks after injection, showing that tumours in the TARBP2-K52R group were detected to be larger than those in the vector group, whereas tumours in the TARBP2-WT group were the smallest (Supplementary Fig. 4c). Here, TARBP2 is linked to neoplasm.